Sales of PENTASA for the six months to June 30, 2007 were $84.0 million, an increase of 34% compared to the same period in 2006 (2006: $62.6 million). Sales growth is higher than prescription growth due to an increasing shift to the 500mg strength units and the impact of a price increase in November 2006.
LIALDA's average market share of the US oral mesalamine market from the launch of LIALDA in March 2007 through to June 30, 2007 was 2.5%. Net sales of $5.0 million for the six months to June 30, 2007 were impacted by $2.1 million in sales deductions, primarily stocking discounts and coupons.
The initial launch stock of $34.3 million (before sales deductions) continues to be worked through the wholesaler pipeline. In accordance with IFRS, sales of LIALDA are being recognized as the conditions for revenue recognition are met. All launch stock is expected to be recognized into revenue by the end of the year.
In Europe, FOSRENOL has now been launched in Germany, France, UK, Italy and a number of other countries. Launches will continue throughout 2007 in the EU, including Spain, subject to finalization of national marketing authorizations and the conclusion of pricing and reimbursement negotiations. European sales of FOSRENOL for the six months to June 30, 2007 were $15.6 million (2006: $0.9 million).
US sales of FOSRENOL for the six months to June 30, 2007 were $31.7
million (2006: $13.0 million) giving worldwide FOSRENOL sales of $47.3
million for the period (2006: $13.9 million). US IMS Retail Audit
prescriptions for the six months to June 30, 2007 were up 12% compared to
the same period in 2006 due to FOSRENOL increasing its average market share
to 8.6% during the six mo
|SOURCE Shire plc|
Copyright©2007 PR Newswire.
All rights reserved